Skip to content

Released Nov 14, 2022, after the close

10-Q filed Nov 14, 2022, 45 days after period end · 0001193125-22-284583

Q3 2022 · 10-Q
Revenue—
Net Income-$10.71MN/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.26N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$11,371,000N/M
Operating Cash Flowderived-$9,183,000N/M
Free Cash Flowderived-$9,264,000N/M

What the release said

The release

Same quarter

MetricQ3 2022Q3 2021Q3 2020
Net Income-$10.71M-$3.90M-$2.49M
EPS Diluted-$0.26-$0.10-$5.94

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR